ACADIA Pharmaceuticals (MEX:ACAD) Other Stockholders Equity: MXN0 Mil (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN360.99
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Other Stockholders Equity?

ACADIA Pharmaceuticals MEX:ACAD 73 Other Stockholders Equity is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN360.99 (Fairly Valued). The stock has 9 warning signs investors should review.

ACADIA Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was MXN0 Mil.

ACADIA Pharmaceuticals's quarterly Other Stockholders Equity stayed the same from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN0 Mil) but then increased from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN0 Mil).

ACADIA Pharmaceuticals's annual Other Stockholders Equity increased from Dec. 2023 (MXN-0 Mil) to Dec. 2024 (MXN-0 Mil) and increased from Dec. 2024 (MXN-0 Mil) to Dec. 2025 (MXN0 Mil).

ACADIA Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Other Stockholders Equity Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of MXN0 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Other Stockholders Equity of MXN0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Other Stockholders Equity too high?
ACADIA Pharmaceuticals' current Other Stockholders Equity is MXN0 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Other Stockholders Equity compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Other Stockholders Equity of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Other Stockholders Equity is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN360.99, compared to a current price of MXN362.00 — trading 0.3% above its estimated fair value. The current Other Stockholders Equity is MXN0 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Other Stockholders Equity is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN362.00 is trading 0.3% above its estimated GF Value™ of MXN360.99. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Other Stockholders Equity: MXN0 Mil
  • GF Value™: MXN360.99 vs. price of MXN362.00 (0.3% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN360.99
GF Value